Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$17.2M | -$25.5M | -$26.4M | -$49.2M | -$136M | -$267M | -$341M | -$277M | -$187M | -$234M |
| Net income | -$17.1M | -$27.9M | -$41.4M | -$47.4M | -$133M | -$267M | -$334M | -$260M | -$176M | -$230M |
| EPS (diluted) | -$2.38 | -$3.72 | -$2.77 | -$1.25 | -$2.91 | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.0M | -$17.7M | -$29.0M | -$39.1M | -$83.4M | -$182M | -$206M | -$154M | -$117M | -$136M |
| Capital expenditures | $771K | $209K | $78.0K | $437K | $3.81M | $17.0M | $37.0M | $41.4M | $375K | $506K |
| Free cash flow | -$16.8M | -$17.9M | -$29.1M | -$39.6M | -$87.2M | -$199M | -$243M | -$196M | -$118M | -$137M |
| Share buybacks | $4.00K | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.62M | $1.40M | $88.3M | $212M | $944M | $732M | $190M | $286M | $168M | $210M |
| Total assets | — | $3.24M | $92.2M | $359M | $1.07B | $904M | $667M | $479M | $336M | $352M |
| Total liabilities | — | $22.0M | $5.36M | $13.5M | $207M | $241M | $230M | $214M | $185M | $194M |
| Shareholders' equity | -$41.1M | -$68.7M | $86.8M | $345M | $861M | $663M | $436M | $266M | $150M | $157M |
| Retained earnings | — | -$69.3M | -$111M | -$158M | -$291M | -$558M | -$892M | -$1.15B | -$1.33B | -$1.56B |
| Shares (wtd avg diluted) | — | 7.94M | 36.8M | 44.4M | 45.7M | 51.8M | 52.2M | 52.4M | 52.6M | 53.2M |
Every figure is extracted from Kodiak Sciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.